Merck News | finanzen.ch

Kurse + Charts + Realtime	News + Analysen	Fundamental	Unternehmen	zugeh. Wertpapiere	Aktion
Kurs + Chart	Chart (gross)	News + Adhoc	Bilanz/GuV	Termine	Strukturierte Produkte	Portfolio
Times + Sales	Chartvergleich	Analysen	Schätzungen	Profil		Watchlist
Börsenplätze	Realtime Push	Kursziele	Dividende/GV
Orderbuch			Analysen
Historisch

Kurse + Charts + Realtime

News + Analysen

Fundamental

Unternehmen

zugeh. Wertpapiere

Aktion

Kurs + Chart

Chart (gross)

News + Adhoc

Bilanz/GuV

Termine

Strukturierte Produkte

Portfolio

Times + Sales

Chartvergleich

Analysen

Schätzungen

Profil

Watchlist

Börsenplätze

Realtime Push

Kursziele

Dividende/GV

Orderbuch

Analysen

Historisch

07.06.06	ZOLINZA(TM), Merck's Investigational Medicine for Advanced Cutaneous T-Cell Lymphoma (CTCL), to Receive Priority Review from U.S. Food and Drug Administration (Businesswire)
11.05.06	Merck Announces Preliminary Analyses of Off-Drug Extension of APPROVe Study (Businesswire)
09.05.06	Merck & Co., Inc. to Acquire Abmaxis, Inc.; Acquisition Further Enhances Merck Commitment and Capabilities in Biologics Research and Development (Businesswire)
09.05.06	Merck & Co., Inc. to Acquire GlycoFi, Inc.; Acquisition Enhances Merck Capabilities in Biologics Research and Development (Businesswire)
25.04.06	Merck Well-Positioned to Regain Industry-Leadership Position, CEO Tells Stockholders (Businesswire)
12.04.06	Presse: Ist Fosamax ein neuer Rechtsstreit für Merck? (n/a)
11.04.06	Merck to Appeal Punitive and Compensatory Verdicts In New Jersey VIOXX(R) Product Liability Case; Merck Pleased that New Jersey Jury Rejected Failure to Warn Claim By One of Two Long-Term VIOXX Users (Businesswire)
05.04.06	Ausblick: Die Märkte am Mittwoch (n/a)
20.03.06	Neuromed Pharmaceuticals and Merck & Co., Inc. Announce Agreement for Novel N-type Calcium Channel Compounds (Businesswire)
13.03.06	New Analysis Showed VYTORIN(R) (ezetimibe/simvastatin) Superior to Lipitor(R) in Achieving Lower Levels of LDL (''bad'') Cholesterol, Apolipoprotein B and C-Reactive Protein (Businesswire)
09.03.06	Merck and Paratek Pharmaceuticals Sign Collaboration Agreement for Novel Antibiotic PTK 0796 Currently in Phase 1 Testing (Businesswire)
02.03.06	The Merck Patient Assistance Program Remains an Option for Many Medicare Beneficiaries (Businesswire)
27.02.06	Rosetta Biosoftware führt Version 6.0 des Systems zur Genexpressionsdatenanalyse Rosetta Resolver ein (Businesswire)
03.02.06	FDA Approves Merck's ROTATEQ(R), The Only Vaccine in the U.S. to Prevent Rotavirus Gastroenteritis, a Leading Cause of Severe Infant Diarrhea; ROTATEQ Fits Into Routine Well-Baby Visit Schedule (Businesswire)
11.01.06	FDA Approves EMEND(R) (aprepitant), in Combination with Other Antiemetics, for the Prevention of Nausea and Vomiting in Cancer Patients Undergoing Moderately Emetogenic Chemotherapy (Businesswire)
10.01.06	VIOXX(R) Trial Update: Statement on VIOXX(R) Product Liability Trial Scheduled in Starr County, Texas (Businesswire)
12.12.05	Hung Jury in First Federal VIOXX(R) Product Liability Trial (Businesswire)
28.11.05	Merck Announces Initial Steps In Global Restructuring Program (Businesswire)
18.11.05	Results of an Initial Phase II Study Showed That MK-0518, an Investigational Integrase Inhibitor, Provided Superior Reduction in HIV Viral RNA vs. Placebo in Treatment-Naive HIV-infected Patients (Businesswire)
15.11.05	Merck/Schering-Plough Announces Update for the IMPROVE-IT Trial (Businesswire)
14.11.05	FDA Approves New Indication for INVANZ(R) (ertapenem) for the Treatment of Moderate to Severe Complicated Foot Infection in Diabetic Patients without Osteomyelitis (Businesswire)
31.10.05	Merck und Bristol-Myers Squibb lizenzieren neue AIDS-Medikamente an IPM zur Entwicklung von Mikrobiziden zum Schutz von Frauen vor HIV (PR Newswire)
24.10.05	Wall Street: Freundlicher Start, Merck überzeugt mit Quartalszahlen (n/a)
24.10.05	Merck Announces Third-Quarter 2005 Earnings Per Share (EPS) of 65 Cents (Businesswire)
03.10.05	Rosetta Biosoftware and Agendia to Deliver Diagnostic Utilities; Agendia Licenses the Rosetta Resolver System (Businesswire)
27.09.05	Merck Expands Katrina Prescription Replacement Program to Include Patients Impacted by Hurricane Rita (Businesswire)
09.09.05	Bristol-Myers Squibb and Merck Joint Statement on FDA Advisory Committee Vote on PARGLUVA(TM) (Muraglitazar), an Investigational Oral Treatment for Type 2 Diabetes (PR Newswire)
18.08.05	Indications for Merck's SINGULAIR(R) Expand with FDA Approval for Perennial Allergic Rhinitis; SINGULAIR Now Shown to Provide Relief from a Broad Range of Indoor and Outdoor Allergy Symptoms (Businesswire)
22.07.05	Ausblick: Die Märkte am Freitag (n/a)
20.05.05	New Study Shows Investigational Compound Muraglitazar Significantly Lowered Blood Glucose Levels As Measured By A1C Reduction in Patients With Type 2 Diabetes (PR Newswire)
02.05.05	Merck Submits Biologics License Application to FDA for ZOSTAVAX-TM-, a (Businesswire)
21.04.05	Wall Street: Unternehmenszahlen und Übernahmen im Fokus (n/a)
21.04.05	Merck Announces First-Quarter 2005 Earnings Per Share -EPS- of 62 Cent (Businesswire)
19.04.05	Merck Announces New Uninsured Discount Program Targeted to More Than 4 (Businesswire)
19.04.05	Study of Breast Cancer Patients Showed Regimen Including EMEND-R- -apr (Businesswire)
14.04.05	FDA Approves HYZAAR as the First and Only Fixed-Dose Combination Hyper (Businesswire)
08.04.05	FDA Approves New FOSAMAX PLUS D - alendronate sodium/cholecalciferol - (Businesswire)
07.04.05	Merck's Investigational Human Papillomavirus -HPV- Vaccine Reduced In (Businesswire)
22.02.05	MORNING UPDATE: Man Securities Inc. issues alerts for MRK, HD, MER, BA (PR Newswire)
07.02.05	Wall Street: Zurückhaltender Wochenauftakt (n/a)
28.01.05	Merck Comments on Court of Appeals' Decision for Merck's Once-weekly (Businesswire)
25.01.05	Merck & Co. gibt Gewinnrückgang bekannt (n/a)
25.01.05	Merck Announces Full-Year 2004 Earnings Per Share -EPS- of $2.61, Four (Businesswire)
11.01.05	Merck & Co. schliesst Kooperationsvertrag mit Diversa (n/a)
07.01.05	Prof. Otte-Kolumne: Merck & Co., Altria, E.ON und die Deutsche Telekom (n/a)
03.01.05	Presse: FDA-Wissenschaftler erwartet mehr Opfer durch Vioxx-Einnahme (n/a)
03.01.05	Prof. Otte-Kolumne: 2005 wird ein Jahr für selektive Strategien (n/a)

Aktien Top/Flop

SMI
SPI
SLI
SMIM
DAX
ESTOXX
Dow Jones
S&P 500
NASDAQ 100
Nikkei 225

19.11.24		Schwacher Handel: Dow Jones beendet den Dienstagshandel mit Verlusten
19.11.24		Gute Stimmung in New York: NASDAQ 100 letztendlich im Plus
19.11.24		Schwacher Handel: Dow Jones legt am Dienstagnachmittag den Rückwärtsgang ein
19.11.24		Gewinne in New York: NASDAQ 100 legt zu
19.11.24		Dow Jones-Handel aktuell: So entwickelt sich der Dow Jones aktuell
19.11.24		Schwache Performance in Europa: Euro STOXX 50 zeigt sich zum Handelsende schwächer
19.11.24		Angespannte Stimmung in Europa: STOXX 50 verliert schlussendlich

19.11.24

Schwacher Handel: Dow Jones beendet den Dienstagshandel mit Verlusten

19.11.24

Gute Stimmung in New York: NASDAQ 100 letztendlich im Plus

19.11.24

Schwacher Handel: Dow Jones legt am Dienstagnachmittag den Rückwärtsgang ein

19.11.24

Gewinne in New York: NASDAQ 100 legt zu

19.11.24

Dow Jones-Handel aktuell: So entwickelt sich der Dow Jones aktuell

19.11.24

Schwache Performance in Europa: Euro STOXX 50 zeigt sich zum Handelsende schwächer

19.11.24

Angespannte Stimmung in Europa: STOXX 50 verliert schlussendlich

Portfolioname Watchlistname
Portfolio
Name
Typ
Valor / ISIN
Börse
Anzahl
Aktueller Kurs
Kurszeit
Kaufpreis
Kaufdatum
Kaufwert	CHF
	Hinzufügen Speichern

Givaudan	3’870.00	1.49 %	K V
Lonza Grp	513.60	1.14 %	K V
Swiss Re	125.25	0.20 %	K V
Holcim	88.46	0.11 %	K V
Kuehne+Nagel Int	210.40	0.00 %	K V
Logitech Intl	68.92	-1.20 %	K V
Part Grp Hldg	1’209.00	-1.47 %	K V
CieFinRichemont	118.90	-1.94 %	K V
Nestle	76.66	-1.94 %	K V
Sonova Hldg	300.40	-5.21 %	K V

Nachrichten zu Merck Co.

Aktien Top/Flop

Merck Peer Group Nachrichten

Meistgelesene Nachrichten